Scleroderma

Scleroderma
Morphea
Classification and external resources
Specialty	Dermatology
ICD-10	L94.0-L94.1, M34
ICD-9-CM	701.0 710.1
MedlinePlus	000429

Scleroderma, also known as systemic sclerosis, is a chronic systemic autoimmune disease characterised by hardening (sclero) of the skin (derma). In the more severe form, it also affects internal organs.^[1][2]

Limited scleroderma involves cutaneous manifestations that mainly affect the hands, arms and face. It was previously called CREST syndrome in reference to the following common manifestations:^[3] calcinosis (the deposition of calcium nodules in the skin), raynaud's phenomenon (exaggerated vasoconstriction in the hands, with fingers undergoing white-blue-red color transitions in the cold), esophageal dysfunction (leading to difficulty swallowing), sclerodactyly (skin thickening on the fingers), and telangiectasias (dilated capillaries on the face, hands and mucous membranes).

Diffuse scleroderma is rapidly progressing and affects a large area of the skin and one or more internal organs, frequently the kidneys, esophagus, heart and/or lungs. This form of scleroderma can be quite disabling. There are no treatments for scleroderma itself, but individual organ system complications are treated.^[4][5]

The prognosis is generally good for limited cutaneous scleroderma persons who escape lung complications, but is worse for those with the diffuse cutaneous disease, particularly in older age and for males. Death occurs most often from lung, heart and kidney complications. In diffuse cutaneous disease, five-year survival is 70% and 10-year survival is 55%.^[6]

The cause of scleroderma is unknown.^[1] It is an autoimmune condition, in which the body's immune system attacks healthy tissues.^[1] Strong associations with certain mutations in HLA genes have been identified.^[7][8] Strong environmental influences have also been implicated in the etiology of scleroderma.^[9][10] Scleroderma was described in 1753 by Carlo Curzio (Ospedale degli Incurabili, Naples).^[11]

Signs and symptoms

Left arm of a scleroderma sufferer, showing skin lesions

Potential signs and symptoms include:^[2][3][6]

• Cardiovascular: Raynaud's phenomenon (is the presenting symptom in 70% of affected persons, occurs in 95% of affected individuals at some time during their illness); healed pitting ulcers on the fingertips; skin and mucousal telangiectasis; palpitations, irregular heart rate and fainting due to conduction abnormalities, hypertension and congestive heart failure.
• Digestive: gastroesophageal reflux disease, bloating, indigestion, loss of appetite, diarrhoea alternating with constipation, sicca syndrome and its complications, loosening of teeth and hoarseness (due to acid reflux).
• Pulmonary: progressive worsening of shortness of breath, chest pain (due to pulmonary artery hypertension) and dry, persistent cough due to interstitial lung disease.
• Musculoskeletal: joint, muscle aches, loss of joint range of motion, carpal tunnel syndrome and muscle weakness.
• Genitourinary: erectile dysfunction, dyspareunia, scleroderma renal crises and kidney failure.
• Other: facial pain due to trigeminal neuralgia, hand paraesthesias, headache, stroke, fatigue, calcinosis and weight loss.

Cause

Scleroderma is caused by genetic and environmental factors.^{[7][8][9][10]} Mutations in HLA genes seem to play a crucial role in the pathogenesis of some cases (but not all), likewise silica, aromatic and chlorinated solvents, ketones, trichloroethylene, welding fumes and white spirits exposure seems to contribute to the condition in a small proportion of affected persons.^{[7][8][9][10][12]}

Pathophysiology

It is characterised by increased synthesis of collagen (leading to the sclerosis), damage to small blood vessels, activation of T lymphocytes and production of altered connective tissues.^[13] Its proposed pathogenesis is the following:^{[14][15][16][17][18]}

• It begins with an inciting event at the level of the vasculature, probably the endothelium. The inciting event is yet to be elucidated but may be a viral agent, oxidative stress or autoimmune. Endothelial cell damage and apoptosis ensue, leading to the vascular leakiness that manifests in early clinical stages as tissue oedema. At this stage it is predominantly a Th1 and Th17-mediated disease.
• After this the vasculature is further compromised by impaired angiogenesis and impaired vasculogenesis (fewer endothelial progenitor cells), likely related to the presence of anti-endothelin cell antibodies. Despite this impaired angiogenesis, elevated levels of pro-angiogenic growth factors like PDGF and VEGF is often seen in persons with the condition. The balance of vasodilation and vasoconstriction becomes off-balance and the net result is vasoconstriction. The damaged endothelium then serves as a point of origin for blood clot formation and further contributes to ischaemia-reperfusion injury and the generation of reactive oxygen species. These later stages are characterised by Th2 polarity.
• The damaged endothelium upregulates adhesion molecules and chemokines to attract leucocytes, which enables the development of innate and adaptive immune responses, including loss of tolerance to various oxidised antigens, which includes topoisomerase I. B cells mature into plasma cells, which furthers the autoimmune component of the condition. T cells differentiate into subsets, including Th2 cells, which play a vital role in tissue fibrosis. Anti–topoisomerase 1 antibodies, in turn, stimulate type I interferon production.
• Fibroblasts are recruited and activated by multiple cytokines and growth factors to generate myofibroblasts. Dysregulated transforming growth factor β (TGF-β) signalling in fibroblasts and myofibroblasts has been observed in multiple studies of scleroderma-affected individuals. Activation of fibroblasts and myofibroblasts leads to excessive deposition of collagen and other related proteins, leading to fibrosis. B cells are implicated in this stage, IL-6 and TGF-β produced by the B cells decrease collagen degradation and increase extracellular matrix production. Endothelin signalling is implicated in the pathophysiology of fibrosis.^[19]

Vitamin D is implicated in the pathophysiology of the disease. An inverse correlation between plasma levels of vitamin D and scleroderma severity has been noted and vitamin D is known to play a crucial role in regulating (usually suppressing) the actions of the immune system.^[20]

Diagnosis

Typical scleroderma is classically defined as symmetrical skin thickening, with about 70% of cases also presenting with Raynaud's phenomenon, nail-fold capillary changes and antinuclear antibodies. Affected individuals may or may not experience systemic organ involvement. There is no single test for scleroderma that works all of the time and hence the diagnosis is often a matter of exclusion. Atypical scleroderma may show any variation of these changes without skin changes or with finger swelling only.^[21]

Laboratory testing can show antitopoisomerase antibodies, like anti-scl70 (causing a diffuse systemic form), or anticentromere antibodies (causing a limited systemic form and the CREST syndrome). Other autoantibodies can be seen, such as anti-U3 or anti-RNA polymerase.^[1]

Differential

Diseases that are often in the differential include:^[22]

• Eosinophilia, a condition in which there are too many eosinophils (a type of immune cell that attacks parasites and is involved in certain allergic reactions) in the blood.
• Eosinophilia-myalgia syndrome, a form of eosinophilia that is caused by L-tryptophan supplements.
• Eosinophilic fasciitis, a disease that affects the connective tissues surrounding skeletal muscles, bones, blood vessels and nerves in the arms and legs.
• Graft-versus-host disease, an autoimmune condition that occurs as a result of bone marrow transplants in which the immune cells from the transplanted bone marrow attack the host's body.
• Mycosis fungoides, a type of cutaneous T cell lymphoma, a rare cancer that causes rashes all over the body.
• Nephrogenic systemic fibrosis, a condition usually caused by kidney failure that causes fibrosis (thickening) of the tissues.
• Primary biliary cirrhosis, an autoimmune disease of the liver.
• Primary pulmonary hypertension
• Complex regional pain syndrome

Classification

Scleroderma is characterised by the appearance of circumscribed or diffuse, hard, smooth, ivory-colored areas that are immobile and which give the appearance of hidebound skin, a disease occurring in both localised and systemic forms:^[23]

• Localised scleroderma
  • Localised morphea
  • Morphea-lichen sclerosus et atrophicus overlap
  • Generalised morphea
  • Atrophoderma of Pasini and Pierini
  • Pansclerotic morphea
  • Morphea profunda
  • Linear scleroderma
• Systemic scleroderma
  • CREST syndrome
  • Progressive systemic sclerosis

Treatment

There is no cure for scleroderma, although relief of symptoms is often achieved. These include^[2][24]

• Raynaud's phenomenon with vasodilators such as calcium channel blockers, alpha blockers, serotonin receptor antagonists, angiotensin II receptor inhibitors, statins, local nitrates or iloprost
• Digital ulcers with phosphodiesterase 5 inhibitors (e.g., sildenafil) or iloprost
• Prevention of new digital ulcers with bosentan
• Malnutrition, secondary to intestinal flora overgrowth with tetracycline antibiotics like tetracycline
• Alveolitis with cyclophosphamide, azathioprine with or without corticosteroids
• Pulmonary arterial hypertension with endothelin receptor antagonists, phosphodiesterase 5 inhibitors and prostanoids
• Gastrooesophageal reflux disease with antacids or prokinetics
• Kidney crises with angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists

Systemic disease-modifying treatment with immunosuppressants is often used.^{[7][25][26][27][28][29]} Immunosuppressants used in its treatment include azathioprine, methotrexate, cyclophosphamide, mycophenolate, intravenous immunoglobulin, rituximab, sirolimus, alefacept and the tyrosine kinase inhibitors, imatinib, nilotinib and dasatinib.^{[7][24][25][26][27][28][29][30]}

Experimental therapies under investigation include endothelin receptor antagonsits, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept and haematopoietic stem cell transplantation.^[31][32]

Immunomodulatory agents in the treatment of scleroderma
INN	Mechanism of action[33][34]	Route of administration[33]	Pregnancy category[33][35]	Major toxicities[33]
Alefacept	Monoclonal antibody to inhibit T lymphocyte activation by binding to CD2 portion of human leukocyte function antigen-3.	IM	B (US)	Malignancies, injection site reactions, blood clots, lymphopenia, hepatotoxicity and infections.
Azathioprine	Purine analogue that inhibits lymphocyte proliferation via conversion to mercaptopurine	PO, IV	D (Au)	Myelosuppression and rarely malignancy, hepatitis, infection, hepatic sinusoidal obstruction syndrome and hypersensitivity reactions.
Cyclophosphamide	Nitrogen mustard that cross-links DNA base pairs, leading to breakages and triggering apoptosis in haematopoietic cells.	PO, IV	D (Au)	Vomiting, myelosuppression, haemorrhagic cystitis and rarely heart failure, pulmonary fibrosis, hepatic sinusoidal obstruction syndrome, malignancy and SIADH.
Dasatinib	Tyrosine kinase inhibitor against various pro-angiogenic growth factors (including PDGF and VEGF).	PO	D (Au)	Fluid retention, myelosuppression, haemorrhage, infections, pulmonary hypertension, electrolyte anomalies and uncommonly hepatotoxicity, heart dysfunction/failure, myocardial infarction, QT interval prolongation, renal failure and hypersensitivity.
Imatinib	As above.	PO	D (Au)	As above and rarely: GI perforation, avascaular necrosis and rhabdomyolysis.
Immunoglobulin	Immunoglobulin, modulates the immune system.	IV	N/A	Varies.
Methotrexate	Antifolate; inhibits dihydrofolate reductase.	PO, IV, IM, SC, IT	D (Au)	Myeosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity and rarely kidney failure, hypersensitivity reactions, skin and bone necrosis and osteoporosis.
Mycophenolate	Inosine monophosphate dehydrogenase inhibitor, leading to reduced purine biosynthesis in lymphocytes.	PO, IV	D (Au)	Myelosuppression, blood clots, less commonly GI perforation/haemorrhage and rarely pancreatitis, hepatitis, aplastic anaemia and pure red cell aplasia.
Nilotinib	As per dasatinib.	PO	D (Au)	As per imatinib.
Rituximab	Monoclonal antibody against CD20 which is expressed on B lymphocytes.	IV	C (Au)	Infusion-related reactions, infection, neutropenia, reduced immunoglobulin levels, arrhythmias, less commonly anaemia, thrombocytopenia, angina, myocardial infarction, heart failure and rarely haemolytic anaemia, aplastic anaemia, serum sickness, severe skin conditions, pulmonary infiltrates, pneumonitis, cranial neuropathy (vision or hearing loss) and progressive multifocal leucoencephalopathy.
Sirolimus	mTOR inhibitor, thereby reducing cytokine-induced lymphocyte proliferation.	PO	C (Au)	Neutropenia, hypokalaemia, interstitial lung disease, pericardial effusion, pleural effusion, less commonly pulmonary haemorrhage, nephrotic syndrome and rarely hepatotoxicity and lymphoedema.
Notes: PO = Oral. IV = Intravenous. IM = Intramuscular. SC = Subcutaneous. IT = Intrathecal. The preferred pregnancy category, above, is Australian, if available. If unavailable an American one is substituted.

Prognosis

The 5-year survival rate for scleroderma is about 85%, whereas the 10-year survival rate is less than 70%.^[36] This varies according to the subtype; for instance, persons with limited skin disease have a 10-year survival rate of 71%, whereas the outlook for patients with systemic scleroderma has generally improved over the years. Ten-year survival rates rose from 54% in 1972 to 66% in 2001^[37] The major causes of death in persons with scleroderma are: pulmonary hypertension, pulmonary fibrosis and scleroderma renal crisis.^[1] People with scleroderma are also at a heightened risk for contracting cancers (especially liver, lung, haematologic and bladder cancers) and, perhaps, cardiovascular disease.^{[38][39][40][41][42]}

Epidemiology

Scleroderma most commonly first presents between the ages of 20 and 50 years, although any age group can be affected.^[1][2] Women are four to nine times more likely to develop scleroderma than men.^[1]

This disease is found worldwide.^[1] In the United States, prevalence is estimated at 240 per million and the annual incidence of scleroderma is 19 per million people.^[1] Likewise in the United States, it is slightly more common in African Americans than in their white counterparts.^[1] In Germany, the prevalence is between 10 and 150 per million people, and the annual incidence is between 3 and 28 per million people.^[36] In South Australia, the annual incidence is 23 per million people, and the prevalence 233 per million people.^[43] Scleroderma is less common in the Asian population.^[44]

Pregnancy

Scleroderma in pregnancy is a complex situation; it increases the risk to both mother and child.^[45] Overall scleroderma is associated with reduced fetal weight for gestational age.^[45] The treatment for scleroderma often includes known teratogens such as cyclophosphamide, methotrexate, mycophenolate, etc. and hence careful avoidance of such drugs during pregnancy is advised.^[45] In these cases hydroxychloroquine and low-dose corticosteroids might be used for disease control.^[45]

See also

• List of cutaneous conditions
• Congenital fascial dystrophy

External links

• Handout on Health: Scleroderma - US National Institute of Arthritis and Musculoskeletal and Skin Diseases

References

1. Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012). Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS, ed. "Scleroderma". Medscape Reference. WebMD. Retrieved 5 March 2014.
2. Hajj-ali, RA (June 2013). "Systemic Sclerosis". Merck Manual Professional. Merck Sharp & Dohme Corp. Retrieved 5 March 2014.
3. Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012). Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS, ed. "Scleroderma Clinical Presentation". Medscape Reference. WebMD. Retrieved 5 March 2014.
4. Gabrielli A, Avvedimento EV, Krieg T (2009). "Scleroderma". New England Journal of Medicine 360 (19): 1989–2003. doi:10.1056/NEJMra0806188. PMID 19420368.
5. Klippel, John H. Primer On the Rheumatic Diseases 11ED. Atlanta, GA: Arthritis Foundation. ISBN 1-912423-16-2.
6. Longo, D; Fauci, A; Kasper, D; Hauser, S; Jameson, J; Loscalzo, J (2011). Harrison's Principles of Internal Medicine (18 ed.). New York: McGraw-Hill Professional. ISBN 978-0-07174889-6.
7. Balbir-Gurman A, Braun-Moscovici Y (February 2012). "Scleroderma – New aspects in pathogenesis and treatment". Best Practice & Research Clinical Rheumatology 26 (1): 13–24. doi:10.1016/j.berh.2012.01.011. PMID 22424190.
8. Greenblatt MB, Aliprantis AO (January 2013). "The immune pathogenesis of scleroderma: context is everything." (PDF). Current Rheumatology Reports 15 (1): 297. doi:10.1007/s11926-012-0297-8. PMC 3539168. PMID 23288576.
9. Barnes J, Mayes MD (March 2012). "Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers.". Current Opinion in Rheumatology 24 (2): 165–70. doi:10.1097/BOR.0b013e32834ff2e8. PMID 22269658.
10. Dospinescu P, Jones GT, Basu N (March 2013). "Environmental risk factors in systemic sclerosis.". Current opinion in rheumatology 25 (2): 179–83. doi:10.1097/BOR.0b013e32835cfc2d. PMID 23287382.
11. http://www.asmn.re.it/lezione-magistrale-a-palazzo-rocca-saporiti-la-sclerodermia-una-malattia-ancora-misteriosa
12. Marie I, Gehanno JF, Bubenheim M, Duval-Modeste AB, Joly P, Dominique S, Bravard P, Noël D, Cailleux AF, Weber J, Lagoutte P, Benichou J, Levesque H (February 2014). "Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature.". Autoimmunity Reviews 13 (2): 151–6. doi:10.1016/j.autrev.2013.10.002. PMID 24129037.
13. Valančienė G, Jasaitienė D, Valiukevičienė S (2010). "Pathogenesis and treatment modalities of localized scleroderma." (PDF). Medicina 46 (10): 649–56. PMID 21393982.
14. Katsumoto TR, Whitfield ML, Connolly MK (2011). "The pathogenesis of systemic sclerosis.". Annual Review of Pathology 6: 509–37. doi:10.1146/annurev-pathol-011110-130312. PMID 21090968.
15. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (August 2011). "Angiogenic cytokines and growth factors in systemic sclerosis.". Autoimmunity Reviews 10 (10): 590–4. doi:10.1016/j.autrev.2011.04.019. PMID 21549861.
16. Cipriani P, Marrelli A, Liakouli V, Di Benedetto P, Giacomelli R (August 2011). "Cellular players in angiogenesis during the course of systemic sclerosis.". Autoimmunity Reviews 10 (10): 641–6. doi:10.1016/j.autrev.2011.04.016. PMID 21549220.
17. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G (August 2011). "B cells in systemic sclerosis: a possible target for therapy.". Autoimmunity Reviews 10 (10): 624–30. doi:10.1016/j.autrev.2011.04.013. PMID 21545850.
18. Hunzelmann N, Krieg T (May 2010). "Scleroderma: from pathophysiology to novel therapeutic approaches." (PDF). Experimental Dermatology 19 (5): 393–400. doi:10.1111/j.1600-0625.2010.01082.x. PMID 20507361.
19. Leask A (June 2011). "The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.". Pharmacological research 63 (6): 502–3. doi:10.1016/j.phrs.2011.01.011. PMID 21315153.
20. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M, Matucci-Cerinic M, Szücs G, Shapira Y, Szekanecz Z, Shoenfeld Y (June 2011). "Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature.". Autoimmunity Reviews 10 (8): 490–4. doi:10.1016/j.autrev.2011.02.002. PMID 21320645.
21. Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012). Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS, ed. "Scleroderma Workup". Medscape Reference. WebMD. Retrieved 6 March 2014.
22. Jimenez, SA; Cronin, PM; Koenig, AS; O'Brien, MS; Castro, SV (15 February 2012). Varga, J; Talavera, F; Goldberg, E; Mechaber, AJ; Diamond, HS, ed. "Scleroderma Differential Diagnoses". Medscape Reference. WebMD. Retrieved 6 March 2014.
23. Elston, William D. James, Timothy G. Berger, Dirk M. (2006). Andrew's diseases of the skin: clinical dermatology (10 ed.). Philadelphia, PA: Saunders Elsevier. pp. 169–172. ISBN 978-0808923510.
24. Walker KM, Pope J (August 2012). "Treatment of systemic sclerosis complications: what to use when first-line treatment fails — a consensus of systemic sclerosis experts.". Seminars in Arthritis and Rheumatism 42 (1): 42–55. doi:10.1016/j.semarthrit.2012.01.003. PMID 22464314.
25. Fett N (July–August 2013). "Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.". Clinics in dermatology 31 (4): 432–7. doi:10.1016/j.clindermatol.2013.01.010. PMID 23806160.
26. Shah AA, Wigley FM (April 2013). "My approach to the treatment of scleroderma.". Mayo Clinic Proceedings 88 (4): 377–93. doi:10.1016/j.mayocp.2013.01.018. PMC 3666163. PMID 23541012.
27. Kowal-Bielecka O, Bielecki M, Kowal K (2013). "Recent advances in the diagnosis and treatment of systemic sclerosis." (PDF). Polskie Archiwum Medycyny Wewnetrznej 123 (1-2): 51–8. PMID 23344666.
28. Beyer C, Dees C, Distler JH (January 2013). "Morphogen pathways as molecular targets for the treatment of fibrosis in systemic sclerosis.". Archives of Dermatological Research 305 (1): 1–8. doi:10.1007/s00403-012-1304-7. PMID 23208311.
29. Leask A (June 2012). "Emerging targets for the treatment of scleroderma.". Expert Opinion on Emerging Drugs 17 (2): 173–9. doi:10.1517/14728214.2012.678833. PMID 22533795.
30. Manno R, Boin F (November 2010). "Immunotherapy of systemic sclerosis." (PDF). Immunotherapy 2 (6): 863–78. doi:10.2217/imt.10.69. PMC 3059511. PMID 21091117.
31. Postlethwaite AE, Harris LJ, Raza SH, Kodura S, Akhigbe T (April 2010). "Pharmacotherapy of systemic sclerosis." (PDF). Expert Opinion on Pharmacotherapy 11 (5): 789–806. doi:10.1517/14656561003592177. PMC 2837533. PMID 20210685.
32. Ong VH, Denton CP (May 2010). "Innovative therapies for systemic sclerosis.". Current Opinion in Rheumatology 22 (3): 264–72. doi:10.1097/BOR.0b013e328337c3d6. PMID 20190640.
33. Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
34. Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
35. "Medscape Multispecialty – Home page". WebMD. Retrieved 27 November 2013.
36. Sticherling M (October 2012). "Systemic sclerosis-dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings.". Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 10 (10): 705–18; quiz 716. doi:10.1111/j.1610-0387.2012.07999.x. PMID 22913330.
37. "Scleroderma Prognosis - Scleroderma Health Information - NY Times Health". www.nytimes.com. Retrieved 2015-09-12.
38. Ngian GS, Sahhar J, Wicks IP, Van Doornum S (August 2011). "Cardiovascular disease in systemic sclerosis--an emerging association?" (PDF). Arthritis Research & Therapy 13 (4): 237. doi:10.1186/ar3445. PMC 3239376. PMID 21888685.
39. Szekanecz É, Szamosi S, Horváth Á, Németh Á, Juhász B, Szántó J, Szücs G, Szekanecz Z (October 2012). "Malignancies associated with systemic sclerosis.". Autoimmunity Reviews 11 (12): 852–5. doi:10.1016/j.autrev.2012.02.021. PMID 22410174.
40. Shah AA, Rosen A (November 2011). "Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications." (PDF). Current Opinion in Rheumatology 23 (6): 530–5. doi:10.1097/BOR.0b013e32834a5081. PMC 3373179. PMID 21825998.
41. Onishi A, Sugiyama D, Kumagai S, Morinobu A (July 2013). "Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies.". Arthritis and Rheumatism 65 (7): 1913–21. doi:10.1002/art.37969. PMID 23576072.
42. Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A (22 November 2012). "Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies" (PDF). Rheumatology 52 (1): 143–154. doi:10.1093/rheumatology/kes303. PMID 23175568.
43. Nikpour M, Stevens WM, Herrick AL, Proudman SM (December 2010). "Epidemiology of systemic sclerosis.". Best Practice & Research Clinical Rheumatology 24 (6): 857–69. doi:10.1016/j.berh.2010.10.007. PMID 21665131.
44. Gelber AC, Manno RL, Shah AA, Woods A, Le EN, Boin F, Hummers LK, Wigley FM (July 2013). "Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.". Medicine 92 (4): 191–205. doi:10.1097/MD.0b013e31829be125. PMID 23793108.
45. Lidar M, Langevitz P (May 2012). "Pregnancy issues in scleroderma.". Autoimmunity Reviews 11 (6-7): A515–9. doi:10.1016/j.autrev.2011.11.021. PMID 22155199.

^[1]

1. "Scleroderma". Scleroderma. New York times. Nov 5, 2013.